Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

TOUJEO SOLOSTAR 300 UNIT/ML

insulin glargine
$91.3482per ML

Strength

300 U/mL

Manufacturer

Sanofi-Aventis U.S. LLC

NDC

00024586903

Classification

Brand

Dosage Form

INJECTION, SOLUTION

Route

SUBCUTANEOUS

Last Updated

4/22/2026

Active Ingredients

INSULIN GLARGINE

Approval Type

Biologic (BLA)

FDA Application

BLA206538

On Market Since

2/15/2015

Pharmacological Classes

Insulin Analog
Insulin

Price History

1W

0.0%

1M

-0.0%

3M

-0.0%

6M

-0.0%

1Y

-0.1%

3Y

+4.9%

5Y

+10.2%

All

+27.6%

Generic Alternatives

Save up to 71%

1 alternative • Same active ingredient

INSULIN GLARGINE SOLOSTAR U300
Generic
00955390003•Sanofi-Aventis U.S. LLC
$26.9353
Save 71%

Related Drugs

Same classification

HUMULIN 70-30 VIAL
Brand
00002871501•Eli Lilly and Company
$4.2626
per ML
HUMULIN R 100 UNIT/ML VIAL
Brand
00002821501•Eli Lilly and Company
$4.2660
per ML
HUMULIN N 100 UNIT/ML VIAL
Brand
00002831501•Eli Lilly and Company
$4.2686
per ML
NOVOLIN R 100 UNIT/ML VIAL
Brand
00169183311•Novo Nordisk
$4.6226
per ML
NOVOLIN N 100 UNIT/ML VIAL
Brand
00169183411•Novo Nordisk
$4.6249
per ML
NOVOLIN 70-30 100 UNIT/ML VIAL
Brand
00169183711•Novo Nordisk
$4.6290
per ML
AFREZZA (REGULAR INSULIN) 4 UNIT CARTRIDGE
Brand
47918087490•Mannkind Corporation
$5.1957
per EA
NOVOLIN R 100 UNIT/ML FLEXPEN
Brand
00169300315•Novo Nordisk
$5.8194
per ML
NOVOLIN 70-30 FLEXPEN
Brand
00169300715•Novo Nordisk
$5.8261
per ML
NOVOLIN N 100 UNIT/ML FLEXPEN
Brand
00169300415•Novo Nordisk
$5.8268
per ML

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy